BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pais R, Barritt AS 4th, Calmus Y, Scatton O, Runge T, Lebray P, Poynard T, Ratziu V, Conti F. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol. 2016;65:1245-1257. [PMID: 27486010 DOI: 10.1016/j.jhep.2016.07.033] [Cited by in Crossref: 190] [Cited by in F6Publishing: 172] [Article Influence: 31.7] [Reference Citation Analysis]
Number Citing Articles
1 Yilmaz Y, Byrne CD, Musso G. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol 2021;15:345-52. [PMID: 33270482 DOI: 10.1080/17474124.2021.1860019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
2 Ciardullo S, Monti T, Perseghin G. Prevalence of Liver Steatosis and Fibrosis Detected by Transient Elastography in Adolescents in the 2017-2018 National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol. 2021;19:384-390.e1. [PMID: 32623006 DOI: 10.1016/j.cgh.2020.06.048] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 12.5] [Reference Citation Analysis]
3 Shetty A, Giron F, Divatia MK, Ahmad MI, Kodali S, Victor D. Nonalcoholic Fatty Liver Disease after Liver Transplant. J Clin Transl Hepatol 2021;9:428-35. [PMID: 34221929 DOI: 10.14218/JCTH.2020.00072] [Reference Citation Analysis]
4 Cillo U, Bechstein WO, Berlakovich G, Dutkowski P, Lehner F, Nadalin S, Saliba F, Schlitt HJ, Pratschke J. Identifying risk profiles in liver transplant candidates and implications for induction immunosuppression. Transplantation Reviews 2018;32:142-50. [DOI: 10.1016/j.trre.2018.04.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
5 Arora M, Kutinová Canová N, Farghali H. mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitis. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.174857] [Reference Citation Analysis]
6 Robinson EJ, Taddeo MC, Chu X, Shi W, Wood C, Still C, Rovnyak VG, Rovnyak D. Aqueous Metabolite Trends for the Progression of Nonalcoholic Fatty Liver Disease in Female Bariatric Surgery Patients by Targeted 1H-NMR Metabolomics. Metabolites 2021;11:737. [PMID: 34822395 DOI: 10.3390/metabo11110737] [Reference Citation Analysis]
7 Mikolasevic I, Milic S, Filipec-Kanizaj T. Fatty liver allografts are associated with primary graft non-function and high mortality after transplantation. Liver Int. 2017;37:1113-1115. [PMID: 28710818 DOI: 10.1111/liv.13453] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
8 Wu X, Ge L, Shen G, He Y, Xu Z, Li D, Mu C, Zhao L, Zhang W. 131I-Labeled Silk Fibroin Microspheres for Radioembolic Therapy of Rat Hepatocellular Carcinoma. ACS Appl Mater Interfaces 2022;14:21848-59. [PMID: 35507826 DOI: 10.1021/acsami.2c00211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Xu J, Cao K, Zhao L, Feng Z, Dong Z, Li J, Liu J. The effects and mechanisms of pomegranate in the prevention and treatment of metabolic syndrome. Tradit Med Mod Med 2020;03:223-37. [DOI: 10.1142/s2575900020300064] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 McPhee MJ, Salsman J, Foster J, Thompson J, Mathavarajah S, Dellaire G, Ridgway ND. Running 'LAPS' Around nLD: Nuclear Lipid Droplet Form and Function. Front Cell Dev Biol 2022;10:837406. [PMID: 35178392 DOI: 10.3389/fcell.2022.837406] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sci 2021;271:119220. [PMID: 33592199 DOI: 10.1016/j.lfs.2021.119220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Maier S, Wieland A, Cree-Green M, Nadeau K, Sullivan S, Lanaspa MA, Johnson RJ, Jensen T. Lean NAFLD: an underrecognized and challenging disorder in medicine. Rev Endocr Metab Disord 2021;22:351-66. [PMID: 33389543 DOI: 10.1007/s11154-020-09621-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
13 Straś W, Małkowski P, Tronina O. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis - epidemiology, risk factors, clinical implications and treatment. Clin Exp Hepatol 2020;6:170-5. [PMID: 33145423 DOI: 10.5114/ceh.2020.99506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Matteo MV, Bove V, Pontecorvi V, De Siena M, Taibi C, Costamagna G, Boškoski I. Endoscopic Sleeve Gastroplasty as a Therapeutic Chance for Obese Patients not Eligible for Organ Transplantation. Obes Surg 2022. [PMID: 35294691 DOI: 10.1007/s11695-022-06008-w] [Reference Citation Analysis]
15 Kizivat T, Maric I, Mudri D, Curcic IB, Primorac D, Smolic M. Hypothyroidism and Nonalcoholic Fatty Liver Disease: Pathophysiological Associations and Therapeutic Implications. J Clin Transl Hepatol 2020;8:347-53. [PMID: 33083258 DOI: 10.14218/JCTH.2020.00027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Eshraghian A, Nikeghbalian S, Kazemi K, Shamsaeefar A, Geramizadeh B, Malek-Hosseini SA. Non-alcoholic fatty liver disease after liver transplantation in patients with non-alcoholic steatohepatitis and cryptogenic cirrhosis: the impact of pre-transplant graft steatosis. HPB (Oxford) 2020;22:521-8. [PMID: 31431413 DOI: 10.1016/j.hpb.2019.07.015] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther. 2017;46:85-95. [PMID: 28464369 DOI: 10.1111/apt.14112] [Cited by in Crossref: 99] [Cited by in F6Publishing: 87] [Article Influence: 19.8] [Reference Citation Analysis]
18 Huh JY, Reilly SM, Abu-Odeh M, Murphy AN, Mahata SK, Zhang J, Cho Y, Seo JB, Hung CW, Green CR, Metallo CM, Saltiel AR. TANK-Binding Kinase 1 Regulates the Localization of Acyl-CoA Synthetase ACSL1 to Control Hepatic Fatty Acid Oxidation. Cell Metab 2020;32:1012-1027.e7. [PMID: 33152322 DOI: 10.1016/j.cmet.2020.10.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
19 Horner R, Gassner JGMV, Kluge M, Tang P, Lippert S, Hillebrandt KH, Moosburner S, Reutzel-Selke A, Pratschke J, Sauer IM, Raschzok N. Impact of Percoll purification on isolation of primary human hepatocytes. Sci Rep 2019;9:6542. [PMID: 31024069 DOI: 10.1038/s41598-019-43042-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Lazarus JV, Cortez-Pinto H, Anstee QM. Reply to: "Caveats for the implementation of global strategies against non-alcoholic fatty liver disease". J Hepatol 2020;73:221-2. [PMID: 32280051 DOI: 10.1016/j.jhep.2020.03.017] [Reference Citation Analysis]
21 Majumdar A, Tsochatzis EA. Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease. Metabolism 2020;111:154291. [DOI: 10.1016/j.metabol.2020.154291] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
22 Farzin L, Asghari S, Rafraf M, Asghari-Jafarabadi M, Shirmohammadi M. No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease. Int J Vitam Nutr Res 2020;90:279-89. [PMID: 30789808 DOI: 10.1024/0300-9831/a000528] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
23 Mu H, Zhou Q, Yang R, Zeng J, Li X, Zhang R, Tang W, Li H, Wang S, Shen T, Huang X, Dou L, Dong J. Naringin Attenuates High Fat Diet Induced Non-alcoholic Fatty Liver Disease and Gut Bacterial Dysbiosis in Mice. Front Microbiol 2020;11:585066. [PMID: 33281780 DOI: 10.3389/fmicb.2020.585066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
24 Safwan M, Collins KM, Abouljoud MS, Salgia R. Outcome of liver transplantation in patients with prior bariatric surgery. Liver Transpl. 2017;23:1415-1421. [PMID: 28752920 DOI: 10.1002/lt.24832] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
25 Ekstedt M, Nasr P, Kechagias S. Natural History of NAFLD/NASH. Curr Hepatol Rep. 2017;16:391-397. [PMID: 29984130 DOI: 10.1007/s11901-017-0378-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 10.2] [Reference Citation Analysis]
26 Sinha RA, Singh BK, Yen PM. Direct effects of thyroid hormones on hepatic lipid metabolism. Nat Rev Endocrinol 2018;14:259-69. [PMID: 29472712 DOI: 10.1038/nrendo.2018.10] [Cited by in Crossref: 190] [Cited by in F6Publishing: 165] [Article Influence: 47.5] [Reference Citation Analysis]
27 Lee J, Vali Y, Boursier J, Spijker R, Anstee QM, Bossuyt PM, Zafarmand MH. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. Liver Int 2021;41:261-70. [PMID: 32946642 DOI: 10.1111/liv.14669] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
28 Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterol Hepatol 2018;41:328-49. [PMID: 29631866 DOI: 10.1016/j.gastrohep.2017.12.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
29 Castillo Tuñón JM, Marín Gómez LM, Suárez Artacho G, Cepeda Franco C, Bernal Bellido C, Álamo Martínez JM, Padillo Ruiz FJ, Gómez Bravo MÁ. Risk Factors for No Valid Liver Graft. Multivariate Study Based on the Variables Included in the Donation Protocol of the National Trasplant Organisation. Cir Esp (Engl Ed) 2020;98:591-7. [PMID: 32507309 DOI: 10.1016/j.ciresp.2020.03.021] [Reference Citation Analysis]
30 Callender C, Attaye I, Nieuwdorp M. The Interaction between the Gut Microbiome and Bile Acids in Cardiometabolic Diseases. Metabolites 2022;12:65. [PMID: 35050187 DOI: 10.3390/metabo12010065] [Reference Citation Analysis]
31 Janardhan SV. Common Misconceptions in Hepatology: Nonalcoholic Fatty Liver Disease. Clin Liver Dis (Hoboken) 2019;13:79-81. [PMID: 30988942 DOI: 10.1002/cld.769] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Lieber SR, Lee RA, Jiang Y, Reuter C, Watkins R, Szempruch K, Gerber DA, Desai CS, DeCherney GS, Barritt AS 4th. The impact of post-transplant diabetes mellitus on liver transplant outcomes. Clin Transplant. 2019;33:e13554. [PMID: 30927288 DOI: 10.1111/ctr.13554] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
33 van Dalem J, Driessen JHM, Burden AM, Stehouwer CDA, Klungel OH, de Vries F, Brouwers MCGJ. Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study. Hepatology 2021;74:2467-77. [PMID: 34129693 DOI: 10.1002/hep.32012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
34 Losurdo G, Castellaneta A, Rendina M, Carparelli S, Leandro G, Di Leo A. Systematic review with meta-analysis: De novo non-alcoholic fatty liver disease in liver-transplanted patients. Aliment Pharmacol Ther. 2018;47:704-714. [PMID: 29359341 DOI: 10.1111/apt.14521] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
35 van der Windt DJ, Sud V, Zhang H, Varley PR, Goswami J, Yazdani HO, Tohme S, Loughran P, O'Doherty RM, Minervini MI, Huang H, Simmons RL, Tsung A. Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis. Hepatology 2018;68:1347-60. [PMID: 29631332 DOI: 10.1002/hep.29914] [Cited by in Crossref: 154] [Cited by in F6Publishing: 134] [Article Influence: 38.5] [Reference Citation Analysis]
36 Altamirano J, Qi Q, Choudhry S, Abdallah M, Singal AK, Humar A, Bataller R, Borhani AA, Duarte-Rojo A. Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease. Transl Gastroenterol Hepatol. 2020;5:31. [PMID: 32258535 DOI: 10.21037/tgh.2019.11.14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
37 Han H, Xue T, Li J, Guo Y, Li X, Wang L, Pei L, Zheng M. Plant sterol ester of α-linolenic acid improved non-alcoholic fatty liver disease by attenuating endoplasmic reticulum stress-triggered apoptosis via activation of the AMPK. J Nutr Biochem 2022;:109072. [PMID: 35660097 DOI: 10.1016/j.jnutbio.2022.109072] [Reference Citation Analysis]
38 Mu HN, Zhou Q, Yang RY, Tang WQ, Li HX, Wang SM, Li J, Chen WX, Dong J. Caffeic acid prevents non-alcoholic fatty liver disease induced by a high-fat diet through gut microbiota modulation in mice. Food Res Int 2021;143:110240. [PMID: 33992352 DOI: 10.1016/j.foodres.2021.110240] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
39 Puthenpura MM, Patel V, Fam J, Katz L, Tichansky DS, Myers S. The Use of Transient Elastography Technology in the Bariatric Patient: a Review of the Literature. Obes Surg 2020;30:5108-16. [PMID: 32981002 DOI: 10.1007/s11695-020-05002-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
40 Friesen CS, Hosey-Cojocari C, Chan SS, Csanaky IL, Wagner JB, Sweeney BR, Friesen A, Fraser JD, Shakhnovich V. Efficacy of Weight Reduction on Pediatric Nonalcoholic Fatty Liver Disease: Opportunities to Improve Treatment Outcomes Through Pharmacotherapy. Front Endocrinol (Lausanne) 2021;12:663351. [PMID: 33927697 DOI: 10.3389/fendo.2021.663351] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Guo F, Estévez-Vázquez O, Benedé-Ubieto R, Maya-Miles D, Zheng K, Gallego-Durán R, Rojas Á, Ampuero J, Romero-Gómez M, Philip K, Egbuniwe IU, Chen C, Simon J, Delgado TC, Martínez-Chantar ML, Sun J, Reissing J, Bruns T, Lamas-Paz A, Moral MGD, Woitok MM, Vaquero J, Regueiro JR, Liedtke C, Trautwein C, Bañares R, Cubero FJ, Nevzorova YA. A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy. Cancers (Basel) 2021;14:192. [PMID: 35008356 DOI: 10.3390/cancers14010192] [Reference Citation Analysis]
42 Cigrovski Berkovic M, Virovic-Jukic L, Bilic-Curcic I, Mrzljak A. Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management. World J Gastroenterol 2020; 26(21): 2740-2757 [PMID: 32550751 DOI: 10.3748/wjg.v26.i21.2740] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
43 Belinchón-Romero I, Bellot P, Romero-Pérez D, Herraiz-Romero I, Marco F, Frances R, Ramos-Rincón JM. Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients. Sci Rep 2021;11:8593. [PMID: 33883616 DOI: 10.1038/s41598-021-88043-8] [Reference Citation Analysis]
44 Yu J, Hao G, Wang D, Liu J, Dong X, Sun Y, Pan Q, Li Y, Shi X, Li L, Cao H. Therapeutic Effect and Location of GFP-Labeled Placental Mesenchymal Stem Cells on Hepatic Fibrosis in Rats. Stem Cells Int. 2017;2017:1798260. [PMID: 28491093 DOI: 10.1155/2017/1798260] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
45 Kriss M, Golden-Mason L, Kaplan J, Mirshahi F, Setiawan VW, Sanyal AJ, Rosen HR. Increased hepatic and circulating chemokine and osteopontin expression occurs early in human NAFLD development. PLoS One 2020;15:e0236353. [PMID: 32730345 DOI: 10.1371/journal.pone.0236353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
46 Zhang J, Tan J, Wang M, Wang Y, Dong M, Ma X, Sun B, Liu S, Zhao Z, Chen L, Liu K, Xin Y, Zhuang L. Lipid-induced DRAM recruits STOM to lysosomes and induces LMP to promote exosome release from hepatocytes in NAFLD. Sci Adv 2021;7:eabh1541. [PMID: 34731006 DOI: 10.1126/sciadv.abh1541] [Reference Citation Analysis]
47 Schattenberg JM, Lazarus JV, Newsome PN, Serfaty L, Aghemo A, Augustin S, Tsochatzis E, de Ledinghen V, Bugianesi E, Romero-Gomez M, Bantel H, Ryder SD, Boursier J, Leroy V, Crespo J, Castera L, Floros L, Atella V, Mestre-Ferrandiz J, Elliott R, Kautz A, Morgan A, Hartmanis S, Vasudevan S, Pezzullo L, Trylesinski A, Cure S, Higgins V, Ratziu V. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. Liver Int 2021;41:1227-42. [PMID: 33590598 DOI: 10.1111/liv.14825] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
48 Jensen T, Niwa K, Hisatome I, Kanbay M, Andres-Hernando A, Roncal-Jimenez CA, Sato Y, Garcia G, Ohno M, Lanaspa MA, Johnson RJ, Kuwabara M. Increased Serum Uric Acid over five years is a Risk Factor for Developing Fatty Liver. Sci Rep. 2018;8:11735. [PMID: 30082907 DOI: 10.1038/s41598-018-30267-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
49 Xiong X, Kuang H, Ansari S, Liu T, Gong J, Wang S, Zhao XY, Ji Y, Li C, Guo L, Zhou L, Chen Z, Leon-Mimila P, Chung MT, Kurabayashi K, Opp J, Campos-Pérez F, Villamil-Ramírez H, Canizales-Quinteros S, Lyons R, Lumeng CN, Zhou B, Qi L, Huertas-Vazquez A, Lusis AJ, Xu XZS, Li S, Yu Y, Li JZ, Lin JD. Landscape of Intercellular Crosstalk in Healthy and NASH Liver Revealed by Single-Cell Secretome Gene Analysis. Mol Cell 2019;75:644-660.e5. [PMID: 31398325 DOI: 10.1016/j.molcel.2019.07.028] [Cited by in Crossref: 148] [Cited by in F6Publishing: 148] [Article Influence: 74.0] [Reference Citation Analysis]
50 Jiang K, Mohammad MK, Dar WA, Kong J, Farris AB. Quantitative assessment of liver fibrosis by digital image analysis reveals correlation with qualitative clinical fibrosis staging in liver transplant patients. PLoS One 2020;15:e0239624. [PMID: 32986732 DOI: 10.1371/journal.pone.0239624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
51 Huang TD, Behary J, Zekry A. Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management. Intern Med J 2020;50:1038-47. [PMID: 31760676 DOI: 10.1111/imj.14709] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 27.0] [Reference Citation Analysis]
52 Zambon Azevedo V, Silaghi CA, Maurel T, Silaghi H, Ratziu V, Pais R. Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease. Front Nutr 2022;8:774030. [DOI: 10.3389/fnut.2021.774030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
53 Castellana M, Biacchi E, Procino F, Casanueva FF, Trimboli P. Very-low-calorie ketogenic diet for the management of obesity, overweight and related disorders. Minerva Endocrinol 2021;46. [DOI: 10.23736/s2724-6507.20.03356-8] [Reference Citation Analysis]
54 Jin J, Gong P, Yang Q, Hui D, Zhang H, Qiu C, Wang N, Yi S, Zheng R, Yang Y, Ren J, Chen S. Noninvasive, quantitative evaluation of hepatic steatosis of donor livers by reference frequency method: A preliminary study. Eur J Radiol 2021;143:109909. [PMID: 34455133 DOI: 10.1016/j.ejrad.2021.109909] [Reference Citation Analysis]
55 Cai J, Zhang XJ, Li H. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. Med Res Rev. 2019;39:328-348. [PMID: 29846945 DOI: 10.1002/med.21515] [Cited by in Crossref: 36] [Cited by in F6Publishing: 43] [Article Influence: 9.0] [Reference Citation Analysis]
56 Miele L, Giorgio V, Liguori A, Petta S, Pastorino R, Arzani D, Alberelli MA, Cefalo C, Marrone G, Biolato M, Rapaccini G, Boccia S, Gasbarrini A, Craxì A, Grieco A. Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2020;30:2103-10. [PMID: 32807638 DOI: 10.1016/j.numecd.2020.06.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Remmerie A, Martens L, Scott CL. Macrophage Subsets in Obesity, Aligning the Liver and Adipose Tissue. Front Endocrinol (Lausanne) 2020;11:259. [PMID: 32411096 DOI: 10.3389/fendo.2020.00259] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
58 Bharij A, Neighbors K, Alonso EM, Mohammad S. Health utility and quality of life in pediatric liver transplant recipients. Pediatr Transplant 2020;24. [DOI: 10.1111/petr.13720] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Cunha GM, Villela-Nogueira CA, Bergman A, Lobo Lopes FPP. Abbreviated mpMRI protocol for diffuse liver disease: a practical approach for evaluation and follow-up of NAFLD. Abdom Radiol (NY) 2018;43:2340-50. [PMID: 29450605 DOI: 10.1007/s00261-018-1504-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
60 Jayakumar S, Loomba R. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Aliment Pharmacol Ther 2019;50:144-58. [PMID: 31149745 DOI: 10.1111/apt.15314] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
61 Liu H, Jayakumar S, Traboulsi M, Lee SS. Cirrhotic cardiomyopathy: Implications for liver transplantation. Liver Transpl. 2017;23:826-835. [PMID: 28407402 DOI: 10.1002/lt.24768] [Cited by in Crossref: 68] [Cited by in F6Publishing: 56] [Article Influence: 17.0] [Reference Citation Analysis]
62 Yue F, Xia K, Wei L, Xing L, Wu S, Shi Y, Lam SM, Shui G, Xiang X, Russell R, Zhang D. Effects of constant light exposure on sphingolipidomics and progression of NASH in high-fat-fed rats. J Gastroenterol Hepatol 2020;35:1978-89. [PMID: 32027419 DOI: 10.1111/jgh.15005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 Durand F. How to improve long-term outcome after liver transplantation? Liver Int. 2018;38 Suppl 1:134-138. [PMID: 29427483 DOI: 10.1111/liv.13651] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
64 Yang Z, Qin W, Huo J, Zhuo Q, Wang J, Wang L. MiR-22 modulates the expression of lipogenesis-related genes and promotes hepatic steatosis in vitro. FEBS Open Bio 2021;11:322-32. [PMID: 33159388 DOI: 10.1002/2211-5463.13026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Kim M, Hwang I, Pagire HS, Pagire SH, Choi W, Choi WG, Yoon J, Lee WM, Song JS, Yoo EK, Lee SM, Kim M, Bae MA, Kim D, Lee H, Lee E, Jeon J, Lee I, Kim H, Ahn JH. Design, Synthesis, and Biological Evaluation of New Peripheral 5HT 2A Antagonists for Nonalcoholic Fatty Liver Disease. J Med Chem 2020;63:4171-82. [DOI: 10.1021/acs.jmedchem.0c00002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Kempegowda P, Melson E, Manolopoulos KN, Arlt W, O'Reilly MW. Implicating androgen excess in propagating metabolic disease in polycystic ovary syndrome. Ther Adv Endocrinol Metab 2020;11:2042018820934319. [PMID: 32637065 DOI: 10.1177/2042018820934319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
67 Seidemann L, Krüger A, Kegel-Hübner V, Seehofer D, Damm G. Influence of Genistein on Hepatic Lipid Metabolism in an In Vitro Model of Hepatic Steatosis. Molecules 2021;26:1156. [PMID: 33671486 DOI: 10.3390/molecules26041156] [Reference Citation Analysis]
68 Pareja E, Gómez-Lechón MJ, Tolosa L. Induced pluripotent stem cells for the treatment of liver diseases: challenges and perspectives from a clinical viewpoint. Ann Transl Med 2020;8:566. [PMID: 32775367 DOI: 10.21037/atm.2020.02.164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Peradze N, Farr OM, Mantzoros CS. Research developments in metabolism 2018. Metabolism 2019;91:70-9. [PMID: 30503805 DOI: 10.1016/j.metabol.2018.11.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
70 Augustin S, Graupera I, Caballeria J; en nombre del grupo de trabajo sobre «Hígado graso no alcohólico» de la Societat Catalana de Digestologia. Non-alcoholic fatty liver disease: A poorly known pandemic. Med Clin (Barc) 2017;149:542-8. [PMID: 28751080 DOI: 10.1016/j.medcli.2017.06.026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
71 Yu Z, Wang S, Hou H, Ma L, Zhu Y. Lipidomic Profiling Reveals the Effect of Egg Components on Nonalcoholic Steatosis in HepG2 Cells and Its Involved Mechanisms. Eur J Lipid Sci Technol 2020;122:1900451. [DOI: 10.1002/ejlt.201900451] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Grønkjær LL, Wernberg C, Lauridsen MM. Non-alcoholic fatty liver disease: the role of the nurse. Gastrointestinal Nursing 2020;18:S15-21. [DOI: 10.12968/gasn.2020.18.sup6.s15] [Reference Citation Analysis]
73 Soret PA, Magusto J, Housset C, Gautheron J. In Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal. J Clin Med 2020;10:E36. [PMID: 33374435 DOI: 10.3390/jcm10010036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Michelotto J, Gassner JMGV, Moosburner S, Muth V, Patel MS, Selzner M, Pratschke J, Sauer IM, Raschzok N. Ex vivo machine perfusion: current applications and future directions in liver transplantation. Langenbecks Arch Surg 2021;406:39-54. [PMID: 33216216 DOI: 10.1007/s00423-020-02014-7] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
75 Schmitz SM, Kroh A, Ulmer TF, Andruszkow J, Luedde T, Brozat JF, Neumann UP, Alizai PH. Evaluation of NAFLD and fibrosis in obese patients - a comparison of histological and clinical scoring systems. BMC Gastroenterol 2020;20:254. [PMID: 32758151 DOI: 10.1186/s12876-020-01400-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
76 Iruarrizaga-lejarreta M, Arretxe E, Alonso C. Using metabolomics to develop precision medicine strategies to treat nonalcoholic steatohepatitis. Expert Review of Precision Medicine and Drug Development 2019;4:283-97. [DOI: 10.1080/23808993.2019.1685379] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Tomic D, Kemp WW, Roberts SK. Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies. Eur J Gastroenterol Hepatol 2018;30:1103-15. [PMID: 30113367 DOI: 10.1097/MEG.0000000000001235] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
78 Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci 2018;75:3313-27. [PMID: 29936596 DOI: 10.1007/s00018-018-2860-6] [Cited by in Crossref: 234] [Cited by in F6Publishing: 231] [Article Influence: 58.5] [Reference Citation Analysis]
79 Burra P, Berenguer M, Pomfret E. The ILTS Consensus Conference on NAFLD/NASH and Liver Transplantation: Setting the Stage. Transplantation 2019;103:19-21. [DOI: 10.1097/tp.0000000000002507] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
80 Mazzola A, Tran Minh M, Charlotte F, Hdiji A, Bernard D, Wendum D, Calmus Y, Conti F. Chronic Hepatitis E Viral Infection After Liver Transplantation: A Regression of Fibrosis After Antiviral Therapy. Transplantation 2017;101:2083-7. [DOI: 10.1097/tp.0000000000001766] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
81 Blazina I, Selph S. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. Syst Rev 2019;8:295. [PMID: 31783920 DOI: 10.1186/s13643-019-1200-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
82 Pisano G, Donato MF, Consonni D, Oberti G, Borroni V, Lombardi R, Invernizzi F, Bertelli C, Caccamo L, Porzio M, Dondossola D, Rossi G, Fargion S, Fracanzani AL. High prevalence of early atherosclerotic and cardiac damage in patients undergoing liver transplantation: Preliminary results. Dig Liver Dis 2020;52:84-90. [PMID: 31521545 DOI: 10.1016/j.dld.2019.07.007] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
83 Bertasso IM, Pietrobon CB, Lopes BP, Peixoto TC, Soares PN, Oliveira E, Manhães AC, Bonfleur ML, Balbo SL, Cabral SS, Gabriel Kluck GE, Atella GC, Gaspar de Moura E, Lisboa PC. Programming of hepatic lipid metabolism in a rat model of postnatal nicotine exposure – Sex-related differences. Environmental Pollution 2020;258:113781. [DOI: 10.1016/j.envpol.2019.113781] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
84 Gitto S, de Maria N, di Benedetto F, Tarantino G, Serra V, Maroni L, Cescon M, Pinna AD, Schepis F, Andreone P, Villa E. De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients. Eur J Gastroenterol Hepatol. 2018;30:766-773. [PMID: 29505475 DOI: 10.1097/meg.0000000000001105] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 5.3] [Reference Citation Analysis]
85 Zhao Y, Jia M, Zhang C, Feng X, Chen J, Li Q, Zhang Y, Xu W, Dong Y, Jiang Y, Liu Y, Huang P. Reproducibility of ultrasound-guided attenuation parameter (UGAP) to the noninvasive evaluation of hepatic steatosis. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-06879-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Kant R, Lu CK, Nguyen HM, Hsiao HH, Chen CJ, Hsiao HP, Lin KJ, Fang CC, Yen CH. 1,2,3,4,6 penta-O-galloyl-β-D-glucose ameliorates high-fat diet-induced nonalcoholic fatty liver disease and maintains the expression of genes involved in lipid homeostasis in mice. Biomed Pharmacother 2020;129:110348. [PMID: 32554245 DOI: 10.1016/j.biopha.2020.110348] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
87 Kogiso T, Tokushige K. Key roles of hepatologists in successful liver transplantation. Hepatol Res 2018;48:608-21. [PMID: 29722107 DOI: 10.1111/hepr.13183] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
88 Pierantonelli I, Svegliati-baroni G. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH. Transplantation 2019;103:e1-e13. [DOI: 10.1097/tp.0000000000002480] [Cited by in Crossref: 73] [Cited by in F6Publishing: 50] [Article Influence: 24.3] [Reference Citation Analysis]
89 Marchisello S, Di Pino A, Scicali R, Urbano F, Piro S, Purrello F, Rabuazzo AM. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int J Mol Sci 2019;20:E1948. [PMID: 31010049 DOI: 10.3390/ijms20081948] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 17.0] [Reference Citation Analysis]
90 Kruger AJ, Fuchs BC, Masia R, Holmes JA, Salloum S, Sojoodi M, Ferreira DS, Rutledge SM, Caravan P, Alatrakchi N. Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis. Hepatol Commun. 2018;2:529-545. [PMID: 29761169 DOI: 10.1002/hep4.1160] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
91 Horiuchi K, Kogiso T, Sagawa T, Taniai M, Kotera Y, Egawa H, Tokushige K. Prevalence of fatty liver disease after liver transplantation and risk factors for recipients and donors. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100670] [Reference Citation Analysis]
92 Paka P, Lieber SR, Lee RA, Desai CS, Dupuis RE, Barritt AS. Perioperative glucose management and outcomes in liver transplant recipients: A qualitative systematic review. World J Transplant 2018; 8(3): 75-83 [PMID: 29988867 DOI: 10.5500/wjt.v8.i3.75] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
93 Liu Z, Jia J, Ning H, Que S, Zhou L, Zheng S. Systematic Evaluation of the Safety Threshold for Allograft Macrovesicular Steatosis in Cadaveric Liver Transplantation. Front Physiol 2019;10:429. [PMID: 31105577 DOI: 10.3389/fphys.2019.00429] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
94 Liu A, Galoosian A, Kaswala D, Li AA, Gadiparthi C, Cholankeril G, Kim D, Ahmed A. Nonalcoholic Fatty Liver Disease: Epidemiology, Liver Transplantation Trends and Outcomes, and Risk of Recurrent Disease in the Graft. J Clin Transl Hepatol. 2018;6:420-424. [PMID: 30637220 DOI: 10.14218/jcth.2018.00010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
95 Levy JJ, Azizgolshani N, Andersen MJ Jr, Suriawinata A, Liu X, Lisovsky M, Ren B, Bobak CA, Christensen BC, Vaickus LJ. A large-scale internal validation study of unsupervised virtual trichrome staining technologies on nonalcoholic steatohepatitis liver biopsies. Mod Pathol 2021;34:808-22. [PMID: 33299110 DOI: 10.1038/s41379-020-00718-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
96 Zhang Q, Ma XF, Dong MZ, Tan J, Zhang J, Zhuang LK, Liu SS, Xin YN. MiR-30b-5p regulates the lipid metabolism by targeting PPARGC1A in Huh-7 cell line. Lipids Health Dis 2020;19:76. [PMID: 32299444 DOI: 10.1186/s12944-020-01261-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
97 Zhang QY, Zhao LP, Tian XX, Yan CH, Li Y, Liu YX, Wang PX, Zhang XJ, Han YL. The novel intracellular protein CREG inhibits hepatic steatosis, obesity, and insulin resistance. Hepatology 2017;66:834-54. [PMID: 28508477 DOI: 10.1002/hep.29257] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
98 Favre G, Laurain A, Aranyi T, Szeri F, Fulop K, Le Saux O, Duranton C, Kauffenstein G, Martin L, Lefthériotis G. The ABCC6 Transporter: A New Player in Biomineralization. Int J Mol Sci 2017;18:E1941. [PMID: 28891970 DOI: 10.3390/ijms18091941] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
99 O'neill S, Napetti S, Cornateanu S, Sutherland AI, Wigmore S, Oniscu GC, Adair A. Impact of body mass index in liver transplantation for nonalcoholic fatty liver disease and alcoholic liver disease. HPB 2017;19:1074-81. [DOI: 10.1016/j.hpb.2017.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
100 Suk KT, Kim DJ. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2019;13:193-204. [PMID: 30791767 DOI: 10.1080/17474124.2019.1569513] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
101 Lonardo A, Mantovani A, Petta S, Carraro A, Byrne CD, Targher G. Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation. Nat Rev Endocrinol 2022. [PMID: 35840803 DOI: 10.1038/s41574-022-00711-5] [Reference Citation Analysis]
102 Wu C, Lu C, Xu C. Short-term and long-term outcomes of liver transplantation using moderately and severely steatotic donor livers: A systematic review. Medicine (Baltimore) 2018;97:e12026. [PMID: 30170411 DOI: 10.1097/MD.0000000000012026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
103 George J, Anstee Q, Ratziu V, Sanyal A. NAFLD: The evolving landscape. J Hepatol 2018;68:227-9. [PMID: 29223512 DOI: 10.1016/j.jhep.2017.11.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
104 Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399:61-116. [PMID: 34863359 DOI: 10.1016/S0140-6736(21)01701-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 39.0] [Reference Citation Analysis]
105 Jeon SK, Lee JM, Joo I, Park SJ. Quantitative Ultrasound Radiofrequency Data Analysis for the Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Using Magnetic Resonance Imaging Proton Density Fat Fraction as the Reference Standard. Korean J Radiol 2021;22:1077-86. [PMID: 33739636 DOI: 10.3348/kjr.2020.1262] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Tang KT, Dufour JF, Chen PH, Hernaez R, Hutfless S. Antitumour necrosis factor-α agents and development of new-onset cirrhosis or non-alcoholic fatty liver disease: a retrospective cohort. BMJ Open Gastroenterol 2020;7:e000349. [PMID: 32377366 DOI: 10.1136/bmjgast-2019-000349] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
107 Puigvehí M, Hashim D, Haber PK, Dinani A, Schiano TD, Asgharpour A, Kushner T, Kakked G, Tabrizian P, Schwartz M, Gurakar A, Dieterich D, Boffetta P, Friedman SL, Llovet JM, Saberi B. Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades. Am J Transplant 2020;20:220-30. [PMID: 31437349 DOI: 10.1111/ajt.15576] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
108 Alvares D, Hoffman S, Stankovic B, Adeli K. Gut peptide and neuroendocrine regulation of hepatic lipid and lipoprotein metabolism in health and disease. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2019;1864:326-34. [DOI: 10.1016/j.bbalip.2018.12.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
109 Zhu B, Chan SL, Li J, Li K, Wu H, Cui K, Chen H. Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment. Front Cardiovasc Med 2021;8:742382. [PMID: 34557535 DOI: 10.3389/fcvm.2021.742382] [Reference Citation Analysis]
110 Kumar DP, Caffrey R, Marioneaux J, Santhekadur PK, Bhat M, Alonso C, Koduru SV, Philip B, Jain MR, Giri SR, Bedossa P, Sanyal AJ. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease. Sci Rep 2020;10:9330. [PMID: 32518275 DOI: 10.1038/s41598-020-66458-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
111 Alferink LJM, Radjabzadeh D, Erler NS, Vojinovic D, Medina-Gomez C, Uitterlinden AG, de Knegt RJ, Amin N, Ikram MA, Janssen HLA, Kiefte-de Jong JC, Metselaar HJ, van Duijn CM, Kraaij R, Darwish Murad S. Microbiomics, Metabolomics, Predicted Metagenomics, and Hepatic Steatosis in a Population-Based Study of 1,355 Adults. Hepatology 2021;73:968-82. [PMID: 32530501 DOI: 10.1002/hep.31417] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
112 DiStefano JK. NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment. Endocrinology 2020;161:bqaa134. [PMID: 32776116 DOI: 10.1210/endocr/bqaa134] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 14.0] [Reference Citation Analysis]
113 Ma Y, Karki S, Brown PM, Lin DD, Podszun MC, Zhou W, Belyaeva OV, Kedishvili NY, Rotman Y. Characterization of essential domains in HSD17B13 for cellular localization and enzymatic activity. J Lipid Res 2020;61:1400-9. [PMID: 32973038 DOI: 10.1194/jlr.RA120000907] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
114 Nascimbeni F, Ballestri S, Machado MV, Mantovani A, Cortez-pinto H, Targher G, Lonardo A. Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert Review of Gastroenterology & Hepatology 2018;12:351-67. [DOI: 10.1080/17474124.2018.1415756] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
115 Choudhary NS, Saigal S. Preventive Strategies for Nonalcoholic Fatty Liver Disease After Liver Transplantation. J Clin Exp Hepatol 2019;9:619-24. [PMID: 31695252 DOI: 10.1016/j.jceh.2019.05.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
116 Rajcic D, Brandt A, Jin CJ, Sánchez V, Engstler AJ, Jung F, Nier A, Baumann A, Bergheim I. Exchanging dietary fat source with extra virgin olive oil does not prevent progression of diet-induced non-alcoholic fatty liver disease and insulin resistance. PLoS One 2020;15:e0237946. [PMID: 32881925 DOI: 10.1371/journal.pone.0237946] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
117 Skat-rørdam J, Pedersen K, Skovsted GF, Gregersen I, Vangsgaard S, Ipsen DH, Latta M, Lykkesfeldt J, Tveden-nyborg P. Vitamin C Deficiency May Delay Diet-Induced NASH Regression in the Guinea Pig. Antioxidants 2022;11:69. [DOI: 10.3390/antiox11010069] [Reference Citation Analysis]
118 Khalid WB, Farhat N, Lavery L, Jarnagin J, Delany JP, Kim K. Non-invasive Assessment of Liver Fat in ob/ob Mice Using Ultrasound-Induced Thermal Strain Imaging and Its Correlation with Hepatic Triglyceride Content. Ultrasound Med Biol 2021;47:1067-76. [PMID: 33468357 DOI: 10.1016/j.ultrasmedbio.2020.12.014] [Reference Citation Analysis]
119 Alqahtani SA, Broering DC, Alghamdi SA, Bzeizi KI, Alhusseini N, Alabbad SI, Albenmousa A, Alfaris N, Abaalkhail F, Al-Hamoudi WK. Changing trends in liver transplantation indications in Saudi Arabia: from hepatitis C virus infection to nonalcoholic fatty liver disease. BMC Gastroenterol 2021;21:245. [PMID: 34074270 DOI: 10.1186/s12876-021-01828-z] [Reference Citation Analysis]
120 Karimian N, Yeh H. Opportunities for Therapeutic Intervention During Machine Perfusion. Curr Transplant Rep 2017;4:141-8. [PMID: 29109929 DOI: 10.1007/s40472-017-0144-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
121 Gassner JMGV, Nösser M, Moosburner S, Horner R, Tang P, Wegener L, Wyrwal D, Claussen F, Arsenic R, Pratschke J, Sauer IM, Raschzok N. Improvement of Normothermic Ex Vivo Machine Perfusion of Rat Liver Grafts by Dialysis and Kupffer Cell Inhibition With Glycine. Liver Transpl 2019;25:275-87. [PMID: 30341973 DOI: 10.1002/lt.25360] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
122 Alferink LJM, Trajanoska K, Erler NS, Schoufour JD, de Knegt RJ, Ikram MA, Janssen HLA, Franco OH, Metselaar HJ, Rivadeneira F, Darwish Murad S. Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution. J Bone Miner Res. 2019;34:1254-1263. [PMID: 31074909 DOI: 10.1002/jbmr.3713] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
123 Kumar DP, Santhekadur PK, Seneshaw M, Mirshahi F, Uram-Tuculescu C, Sanyal AJ. A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. Hepatology 2019;69:1520-34. [PMID: 30394550 DOI: 10.1002/hep.30346] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
124 Salmanroghani H, Salmanroghani R, Nourian M, Khayarn K, Lahmi F, Iravani S. Evaluation of neck circumference as an easy and reliable predictor for non-alcoholic fatty liver disease. Turk J Gastroenterol 2019;30:163-70. [PMID: 30541716 DOI: 10.5152/tjg.2018.18004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
125 Zhan J, Cao H, Hu T, Shen J, Wang W, Wu P, Yang G, Ho CT, Li S. Efficient Preparation of Black Tea Extract (BTE) with the High Content of Theaflavin Mono- and Digallates and the Protective Effects of BTE on CCl4-Induced Rat Liver and Renal Injury. J Agric Food Chem 2021;69:5938-47. [PMID: 34003645 DOI: 10.1021/acs.jafc.1c01851] [Reference Citation Analysis]
126 Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, Aguilar Schall R, Jia C, McColgan B, Djedjos CS, McHutchison JG, Subramanian GM, Myers RP, Younossi Z, Muir AJ, Afdhal NH, Bosch J, Goodman Z. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. Hepatology 2019;70:1913-27. [PMID: 30993748 DOI: 10.1002/hep.30664] [Cited by in Crossref: 114] [Cited by in F6Publishing: 105] [Article Influence: 38.0] [Reference Citation Analysis]
127 Younossi ZM, Stepanova M, Henry L, Racila A, Lam B, Pham HT, Hunt S. A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD. Liver Int 2017;37:1209-18. [PMID: 28211165 DOI: 10.1111/liv.13391] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
128 Claussen F, Gassner JMGV, Moosburner S, Wyrwal D, Nösser M, Tang P, Wegener L, Pohl J, Reutzel-Selke A, Arsenic R, Pratschke J, Sauer IM, Raschzok N. Dual versus single vessel normothermic ex vivo perfusion of rat liver grafts using metamizole for vasodilatation. PLoS One 2020;15:e0235635. [PMID: 32614897 DOI: 10.1371/journal.pone.0235635] [Reference Citation Analysis]
129 Zeair S, Rajchert J, Stasiuk R, Cyprys S, Miętkiewski J, Zasada-Cedro K, Karpińska E, Duczkowska M, Parczewski M, Wawrzynowicz-Syczewska M. Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Single-Center Experience. Ann Transplant 2019;24:499-505. [PMID: 31439828 DOI: 10.12659/AOT.918150] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
130 C. Gordon S, Fraysse J, Li S, Ozbay AB, Wong RJ. Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients. Am J Gastroenterol 2020;115:562-74. [DOI: 10.14309/ajg.0000000000000484] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
131 Parks E, Yki-Järvinen H, Hawkins M. Out of the frying pan: dietary saturated fat influences nonalcoholic fatty liver disease. J Clin Invest 2017;127:454-6. [PMID: 28112684 DOI: 10.1172/JCI92407] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
132 Zhang W, Cao D, Wang M, Wu Y, Gong J, Li J, Liu Y. XBP1s repression regulates Kupffer cell polarization leading to immune suppressive effects protecting liver allograft in rats. Int Immunopharmacol 2021;91:107294. [PMID: 33395585 DOI: 10.1016/j.intimp.2020.107294] [Reference Citation Analysis]
133 Alam S, Eslam M, Skm Hasan N, Anam K, Chowdhury MAB, Khan MAS, Hasan MJ, Mohamed R. Risk factors of nonalcoholic fatty liver disease in lean body mass population: A systematic review and meta-analysis. JGH Open 2021;5:1236-49. [PMID: 34816009 DOI: 10.1002/jgh3.12658] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Ferguson AE, Xanthakos SA, Siegel RM. Challenges in Screening for Pediatric Nonalcoholic Fatty Liver Disease. Clin Pediatr (Phila) 2018;57:558-62. [DOI: 10.1177/0009922817733300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
135 Tucker B, Li H, Long X, Rye K, Ong KL. Fibroblast growth factor 21 in non-alcoholic fatty liver disease. Metabolism 2019;101:153994. [DOI: 10.1016/j.metabol.2019.153994] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 14.3] [Reference Citation Analysis]
136 El-kady RR, Ali AK, El Wakeel LM, Sabri NA, Shawki MA. Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial. Therapeutic Advances in Chronic Disease 2022;13:204062232210779. [DOI: 10.1177/20406223221077958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
137 Li C, Wang K, Guo L, Sun H, Huang H, Lin X, Li Q. Inhibition of miR-34a-5p alleviates hypoxia-reoxygenation injury by enhancing autophagy in steatotic hepatocytes. Biol Open 2018;7:bio033290. [PMID: 29581146 DOI: 10.1242/bio.033290] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
138 Liu Y, Wu H, Wang Z, Wu J, Ying S, Huang M, Li Y. Integrated expression profiles of mRNA and miRNA in a gerbil model of fatty liver fibrosis treated with exenatide. Clin Res Hepatol Gastroenterol 2021;45:101312. [PMID: 33592427 DOI: 10.1016/j.clinre.2019.07.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Zhu W, Luo H, Xiong M, Shen T. Xiaochaihu decoction for nonalcoholic fatty liver disease: A protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e25267. [PMID: 33761728 DOI: 10.1097/MD.0000000000025267] [Reference Citation Analysis]
140 Fan JG, Wei L, Zhuang H; National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Disease Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). J Dig Dis 2019;20:163-73. [PMID: 30444584 DOI: 10.1111/1751-2980.12685] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
141 Zheng J, Wu H, Zhang Z, Yao S. Dynamic co-expression modular network analysis in nonalcoholic fatty liver disease. Hereditas 2021;158:31. [PMID: 34419146 DOI: 10.1186/s41065-021-00196-8] [Reference Citation Analysis]
142 Sharma L, Gupta D, Abdullah ST. Thioacetamide potentiates high cholesterol and high fat diet induced steato-hepatitic changes in livers of C57BL/6J mice: A novel eight weeks model of fibrosing NASH. Toxicology Letters 2019;304:21-9. [DOI: 10.1016/j.toxlet.2019.01.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
143 Wang X, Li Q, Pang J, Lin J, Liu Y, Xu Z, Zhang H, Shen T, Chen X, Ma J, Xu X, Ling W, Chen Y. Associations between serum total, free and bioavailable testosterone and non-alcoholic fatty liver disease in community-dwelling middle-aged and elderly women. Diabetes Metab 2021;47:101199. [PMID: 33058967 DOI: 10.1016/j.diabet.2020.09.007] [Reference Citation Analysis]
144 Moosburner S, Gassner JMGV, Nösser M, Pohl J, Wyrwal D, Claussen F, Ritschl PV, Dragun D, Pratschke J, Sauer IM, Raschzok N. Prevalence of Steatosis Hepatis in the Eurotransplant Region: Impact on Graft Acceptance Rates. HPB Surg 2018;2018:6094936. [PMID: 30515073 DOI: 10.1155/2018/6094936] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
145 Han MAT, Olivo R, Choi CJ, Pyrsopoulos N. De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation. World J Hepatol 2021; 13(12): 1991-2004 [DOI: 10.4254/wjh.v13.i12.1991] [Reference Citation Analysis]
146 Nasr P, Iredahl F, Dahlström N, Rådholm K, Henriksson P, Cedersund G, Dahlqvist Leinhard O, Ebbers T, Alfredsson J, Carlhäll CJ, Lundberg P, Kechagias S, Ekstedt M. Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol. BMC Gastroenterol 2021;21:180. [PMID: 33879084 DOI: 10.1186/s12876-021-01763-z] [Reference Citation Analysis]
147 Wang J, Conti DV, Bogumil D, Sheng X, Noureddin M, Wilkens LR, Le Marchand L, Rosen HR, Haiman CA, Setiawan VW. Association of Genetic Risk Score With NAFLD in An Ethnically Diverse Cohort. Hepatol Commun 2021;5:1689-703. [PMID: 34558842 DOI: 10.1002/hep4.1751] [Reference Citation Analysis]
148 Han A, Zhang YN, Boehringer AS, Montes V, Andre MP, Erdman JW Jr, Loomba R, Valasek MA, Sirlin CB, O'Brien WD Jr. Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease by Using Quantitative US. Radiology 2020;295:106-13. [PMID: 32013792 DOI: 10.1148/radiol.2020191152] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
149 McCabe P, Wong RJ. More severe deficits in functional status associated with higher mortality among adults awaiting liver transplantation. Clin Transplant 2018;32:e13346. [PMID: 29979466 DOI: 10.1111/ctr.13346] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
150 Sotiropoulou M, Katsaros I, Vailas M, Lidoriki I, Papatheodoridis GV, Kostomitsopoulos NG, Valsami G, Tsaroucha A, Schizas D. Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications. Saudi J Gastroenterol 2021;27:319-30. [PMID: 34810376 DOI: 10.4103/sjg.sjg_249_21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Aller R, Fernández-rodríguez C, lo Iacono O, Bañares R, Abad J, Carrión JA, García-monzón C, Caballería J, Berenguer M, Rodríguez-perálvarez M, Miranda JL, Vilar-gómez E, Crespo J, García-cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-gómez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterología y Hepatología (English Edition) 2018;41:328-49. [DOI: 10.1016/j.gastre.2018.05.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 Ye J, Lin Y, Wang Q, Li Y, Zhao Y, Chen L, Wu Q, Xu C, Zhou C, Sun Y, Ye W, Bai F, Zhou T. Integrated Multichip Analysis Identifies Potential Key Genes in the Pathogenesis of Nonalcoholic Steatohepatitis. Front Endocrinol (Lausanne) 2020;11:601745. [PMID: 33324350 DOI: 10.3389/fendo.2020.601745] [Reference Citation Analysis]
153 Ghodsian N, Abner E, Emdin CA, Gobeil É, Taba N, Haas ME, Perrot N, Manikpurage HD, Gagnon É, Bourgault J, St-Amand A, Couture C, Mitchell PL, Bossé Y, Mathieu P, Vohl MC, Tchernof A, Thériault S, Khera AV, Esko T, Arsenault BJ. Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease. Cell Rep Med 2021;2:100437. [PMID: 34841290 DOI: 10.1016/j.xcrm.2021.100437] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
154 Chen Y, Tang D, Wu H, Wu Y, Yuan T, Zhang H, Jiao Y, Yu W, Yan H. Assessment of long-term functional maintenance of primary human hepatocytes to predict drug-induced hepatoxicity in vitro. Arch Toxicol 2021;95:2431-42. [PMID: 33852043 DOI: 10.1007/s00204-021-03050-y] [Reference Citation Analysis]
155 Xiong X, Wang Q, Wang S, Zhang J, Liu T, Guo L, Yu Y, Lin JD. Mapping the molecular signatures of diet-induced NASH and its regulation by the hepatokine Tsukushi. Mol Metab 2019;20:128-37. [PMID: 30595550 DOI: 10.1016/j.molmet.2018.12.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
156 Chen S, Chao S, Konerman M, Zhang W, Rao H, Wu E, Lin A, Wei L, Lok AS. Survey of Nonalcoholic Fatty Liver Disease Knowledge, Nutrition, and Physical Activity Patterns Among the General Public in Beijing, China. Dig Dis Sci 2019;64:3480-8. [PMID: 31273595 DOI: 10.1007/s10620-019-05709-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
157 Buzás GM. Helicobacter pylori and non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol 2020;66:267-79. [PMID: 32724031 DOI: 10.23736/S1121-421X.20.02671-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
158 Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol 2021. [PMID: 34741169 DOI: 10.1038/s41577-021-00639-3] [Reference Citation Analysis]
159 Simas AM, Kramer CD, Genco CA. Diet-Induced Non-alcoholic Fatty Liver Disease and Associated Gut Dysbiosis Are Exacerbated by Oral Infection. Front Oral Health 2022;2:784448. [DOI: 10.3389/froh.2021.784448] [Reference Citation Analysis]
160 Baratta F, Pastori D, Polimeni L, Bucci T, Ceci F, Calabrese C, Ernesti I, Pannitteri G, Violi F, Angelico F, Del Ben M. Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance. Am J Gastroenterol. 2017;112:1832-1839. [PMID: 29063908 DOI: 10.1038/ajg.2017.371] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 11.0] [Reference Citation Analysis]
161 Malinen MM, Ali I, Bezençon J, Beaudoin JJ, Brouwer KLR. Organic solute transporter OSTα/β is overexpressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury. Am J Physiol Gastrointest Liver Physiol 2018;314:G597-609. [PMID: 29420067 DOI: 10.1152/ajpgi.00310.2017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
162 Vasco M, Paolillo R, Schiano C, Sommese L, Cuomo O, Napoli C. Compromised nutritional status in patients with end-stage liver disease: Role of gut microbiota. Hepatobiliary Pancreat Dis Int 2018;17:290-300. [PMID: 30173786 DOI: 10.1016/j.hbpd.2018.06.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
163 Serin A, Sahin T, Arikan BT, Emek E, Bozkurt B, Tokat Y. A Changing Etiologic Scenario in Liver Transplantation: A Single-Center Cohort Study From Turkey. Transplant Proc 2019;51:2416-9. [PMID: 31402253 DOI: 10.1016/j.transproceed.2019.01.190] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
164 Gruneau L, Ekstedt M, Kechagias S, Henriksson M. Disease progression modelling for economic evaluation in non-alcoholic fatty liver disease - a systematic review. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01153-8. [PMID: 34757199 DOI: 10.1016/j.cgh.2021.10.040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
165 Baldwin D, Chennakesavalu M, Gangemi A. Systematic review and meta-analysis of Roux-en-Y gastric bypass against laparoscopic sleeve gastrectomy for amelioration of NAFLD using four criteria. Surg Obes Relat Dis 2019;15:2123-30. [PMID: 31711944 DOI: 10.1016/j.soard.2019.09.060] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
166 Taher M, Toossi MN, Jafarian A, Rasti A, Nayeri ND. Patients' Experiences of Life Challenges After Liver Transplantation: A Qualitative Study. J Patient Exp 2021;8:2374373521996956. [PMID: 34179375 DOI: 10.1177/2374373521996956] [Reference Citation Analysis]
167 Choi W, Namkung J, Hwang I, Kim H, Lim A, Park HJ, Lee HW, Han KH, Park S, Jeong JS, Bang G, Kim YH, Yadav VK, Karsenty G, Ju YS, Choi C, Suh JM, Park JY. Serotonin signals through a gut-liver axis to regulate hepatic steatosis. Nat Commun. 2018;9:4824. [PMID: 30446669 DOI: 10.1038/s41467-018-07287-7] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 12.0] [Reference Citation Analysis]
168 Jensen T, Wieland A, Cree-Green M, Nadeau K, Sullivan S. Clinical workup of fatty liver for the primary care provider. Postgrad Med 2019;131:19-30. [PMID: 30496690 DOI: 10.1080/00325481.2019.1546532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
169 Laouirem S, Sannier A, Norkowski E, Cauchy F, Doblas S, Rautou PE, Albuquerque M, Garteiser P, Sognigbé L, Raffenne J, van Beers BE, Soubrane O, Bedossa P, Cros J, Paradis V. Endothelial fatty liver binding protein 4: a new targetable mediator in hepatocellular carcinoma related to metabolic syndrome. Oncogene 2019;38:3033-46. [PMID: 30575815 DOI: 10.1038/s41388-018-0597-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
170 Shaheen M, Schrode KM, Pan D, Kermah D, Puri V, Zarrinpar A, Elisha D, Najjar SM, Friedman TC. Sex-Specific Differences in the Association Between Race/Ethnicity and NAFLD Among US Population. Front Med (Lausanne) 2021;8:795421. [PMID: 34926533 DOI: 10.3389/fmed.2021.795421] [Reference Citation Analysis]
171 Zhao XY, Xiong X, Liu T, Mi L, Peng X, Rui C, Guo L, Li S, Li X, Lin JD. Long noncoding RNA licensing of obesity-linked hepatic lipogenesis and NAFLD pathogenesis. Nat Commun 2018;9:2986. [PMID: 30061575 DOI: 10.1038/s41467-018-05383-2] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 13.5] [Reference Citation Analysis]
172 Gessain G, Blériot C, Ginhoux F. Non-genetic Heterogeneity of Macrophages in Diseases-A Medical Perspective. Front Cell Dev Biol 2020;8:613116. [PMID: 33381508 DOI: 10.3389/fcell.2020.613116] [Reference Citation Analysis]
173 Barritt AS. Nonalcoholic Fatty Liver Disease: Epidemiology, Assessments, and Interventions Entering 2021. Clin Ther 2021;43:436-7. [PMID: 33618858 DOI: 10.1016/j.clinthera.2021.01.022] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Ramos LF, Silva CM, Pansa CC, Moraes KCM. Non-alcoholic fatty liver disease: molecular and cellular interplays of the lipid metabolism in a steatotic liver. Expert Rev Gastroenterol Hepatol 2021;15:25-40. [PMID: 32892668 DOI: 10.1080/17474124.2020.1820321] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
175 Hanson A, Wilhelmsen D, DiStefano JK. The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD). Noncoding RNA 2018;4:E18. [PMID: 30134610 DOI: 10.3390/ncrna4030018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
176 Steggerda JA, Bloom MB, Noureddin M, Brennan TV, Todo T, Nissen NN, Klein AS, Kim IK. Higher thresholds for the utilization of steatotic allografts in liver transplantation: Analysis from a U.S. national database. PLoS One 2020;15:e0230995. [PMID: 32240235 DOI: 10.1371/journal.pone.0230995] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
177 Rinella ME, Trotter JF, Abdelmalek MF, Paredes AH, Connelly MA, Jaros MJ, Ling L, Rossi SJ, DePaoli AM, Harrison SA. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. J Hepatol. 2019;70:735-744. [PMID: 30529590 DOI: 10.1016/j.jhep.2018.11.032] [Cited by in Crossref: 27] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
178 Kaufmann B, Reca A, Wang B, Friess H, Feldstein AE, Hartmann D. Mechanisms of nonalcoholic fatty liver disease and implications for surgery. Langenbecks Arch Surg 2021;406:1-17. [PMID: 32833053 DOI: 10.1007/s00423-020-01965-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
179 Saleh FA, Jaber H, Eid A. Effect of Adipose derived mesenchymal stem cells on multiple Organ Injuries in diet-induced obese mice. Tissue Barriers 2021;:1952150. [PMID: 34308754 DOI: 10.1080/21688370.2021.1952150] [Reference Citation Analysis]
180 Iannucci LF, Cioffi F, Senese R, Goglia F, Lanni A, Yen PM, Sinha RA. Metabolomic analysis shows differential hepatic effects of T2 and T3 in rats after short-term feeding with high fat diet. Sci Rep 2017;7:2023. [PMID: 28515456 DOI: 10.1038/s41598-017-02205-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
181 Draijer LG, Haggenburg S, Benninga MA, Chegary M, Koot BGP. Survey on screening for paediatric non-alcoholic fatty liver disease in clinical practice in Dutch hospitals. Acta Paediatr 2020;109:2388-93. [PMID: 32271954 DOI: 10.1111/apa.15294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
182 Kweon M, Kim JY, Jun JH, Kim GJ. Research Trends in the Efficacy of Stem Cell Therapy for Hepatic Diseases Based on MicroRNA Profiling. Int J Mol Sci 2020;22:E239. [PMID: 33383629 DOI: 10.3390/ijms22010239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
183 Hartl L, Elias J, Prager G, Reiberger T, Unger LW. Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease. World J Gastroenterol 2021; 27(19): 2281-2298 [PMID: 34040322 DOI: 10.3748/wjg.v27.i19.2281] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Wu MJ, Fang QL, Zou SY, Zhu Y, Lu W, Du X, Shi BM. Influencing factors for hepatic fat accumulation in patients with type 2 diabetes mellitus. World J Clin Cases 2021; 9(26): 7717-7728 [PMID: 34621822 DOI: 10.12998/wjcc.v9.i26.7717] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
185 Villeret F, Dumortier J, Erard-Poinsot D. How will NAFLD change the liver transplant landscape in the 2020s? Clin Res Hepatol Gastroenterol 2021;:101759. [PMID: 34311133 DOI: 10.1016/j.clinre.2021.101759] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
186 Schleicher J, Dahmen U. Computational Modeling of Oxidative Stress in Fatty Livers Elucidates the Underlying Mechanism of the Increased Susceptibility to Ischemia/Reperfusion Injury. Comput Struct Biotechnol J 2018;16:511-22. [PMID: 30505404 DOI: 10.1016/j.csbj.2018.10.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
187 Alferink LJ, Kiefte-de Jong JC, Erler NS, Veldt BJ, Schoufour JD, de Knegt RJ, Ikram MA, Metselaar HJ, Janssen H, Franco OH, Darwish Murad S. Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study. Gut 2019;68:1088-98. [PMID: 30064987 DOI: 10.1136/gutjnl-2017-315940] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 20.7] [Reference Citation Analysis]
188 Alferink LJM, Kiefte-de Jong JC, Erler NS, de Knegt RJ, Hoorn EJ, Ikram MA, Janssen HLA, Metselaar HJ, Franco OH, Darwish Murad S. Diet-Dependent Acid Load-The Missing Link Between an Animal Protein-Rich Diet and Nonalcoholic Fatty Liver Disease? J Clin Endocrinol Metab 2019;104:6325-37. [PMID: 30977830 DOI: 10.1210/jc.2018-02792] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
189 Zhou JH, Cai JJ, She ZG, Li HL. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice. World J Gastroenterol 2019; 25(11): 1307-1326 [PMID: 30918425 DOI: 10.3748/wjg.v25.i11.1307] [Cited by in CrossRef: 84] [Cited by in F6Publishing: 71] [Article Influence: 28.0] [Reference Citation Analysis]
190 Yin J, Chen X, Zhang F, Zhao M. RMRP inhibition prevents NAFLD progression in rats via regulating miR-206/PTPN1 axis. Mamm Genome 2022. [PMID: 35141790 DOI: 10.1007/s00335-022-09945-0] [Reference Citation Analysis]
191 Mcneice K, Sandberg K. Updates in non-alcoholic fatty liver disease (NAFLD). Current Problems in Pediatric and Adolescent Health Care 2020;50:100844. [DOI: 10.1016/j.cppeds.2020.100844] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
192 Wang L, Pan M, Lo C, Zhao H, Li S, Ho C, Yang G. Anti-fibrotic activity of polyphenol-enriched sugarcane extract in rats via inhibition of p38 and JNK phosphorylation. Food Funct 2018;9:951-8. [DOI: 10.1039/c7fo01617d] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
193 Zhao Y, Zhang C, Xu S, Zhang H, Wei S, Huang P, Zhang L, Wong YN, Xu W, Huang P. Quantitative evaluation of hepatic steatosis using novel ultrasound technology normalized local variance (NLV) and its standard deviation with different ROIs in patients with metabolic-associated fatty liver disease: a pilot study. Abdom Radiol (NY) 2022;47:693-703. [PMID: 34958409 DOI: 10.1007/s00261-021-03394-0] [Reference Citation Analysis]
194 Bethea ED, Samur S, Kanwal F, Ayer T, Hur C, Roberts MS, Terrault N, Chung RT, Chhatwal J. Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy. Clin Gastroenterol Hepatol. 2019;17:739-747.e8. [PMID: 30138735 DOI: 10.1016/j.cgh.2018.08.042] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
195 Jiang ZJ, Shen QH, Chen HY, Yang Z, Shuai MQ, Zheng SS. Galectin-1 gene silencing inhibits the activation and proliferation but induces the apoptosis of hepatic stellate cells from mice with liver fibrosis. Int J Mol Med 2019;43:103-16. [PMID: 30365068 DOI: 10.3892/ijmm.2018.3950] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
196 Labenz C, Nagel M, Kremer WM, Hilscher M, Schilling CA, Toenges G, Kuchen R, Schattenberg JM, Galle PR, Wörns MA. Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis. Aliment Pharmacol Ther 2020;52:527-36. [PMID: 32598080 DOI: 10.1111/apt.15915] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
197 Zhao Z, Wang J, Ren W, Bian Y, Wang Y, Wang L, Guo L, Lei J, Jia J, Miao J. Effect of Jiangan-Jiangzhi Pill on Gut Microbiota and Chronic Inflammatory Response in Rats with Non-Alcoholic Fatty Liver. Chem Biodivers 2022;19:e202100987. [PMID: 35324083 DOI: 10.1002/cbdv.202100987] [Reference Citation Analysis]
198 Tao Y, Xu S, Wang J, Xu L, Zhang C, Chen K, Lian Z, Zhou J, Xie H, Zheng S, Xu X. Delivery of microRNA-33 Antagomirs by Mesoporous Silica Nanoparticles to Ameliorate Lipid Metabolic Disorders. Front Pharmacol 2020;11:921. [PMID: 32848718 DOI: 10.3389/fphar.2020.00921] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
199 Fang C, Sidhu PS. Ultrasound-based liver elastography: current results and future perspectives. Abdom Radiol (NY) 2020;45:3463-72. [PMID: 32918106 DOI: 10.1007/s00261-020-02717-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
200 de Oliveira FL, Panera N, De Stefanis C, Mosca A, D'Oria V, Crudele A, De Vito R, Nobili V, Alisi A. The Number of Liver Galectin-3 Positive Cells Is Dually Correlated with NAFLD Severity in Children. Int J Mol Sci 2019;20:E3460. [PMID: 31337151 DOI: 10.3390/ijms20143460] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
201 A. Sherif Z. The Rise in the Prevalence of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. In: Hamdy Gad E, editor. Nonalcoholic Fatty Liver Disease - An Update. IntechOpen; 2019. [DOI: 10.5772/intechopen.85780] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
202 Koeckerling D, Tomlinson JW, Cobbold JF. Fighting liver fat. Endocr Connect 2020;9:R173-86. [PMID: 32621584 DOI: 10.1530/EC-20-0174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
203 Petersen MC, Samuel VT, Petersen KF, Shulman GI. Non‐alcoholic Fatty Liver Disease and Insulin Resistance. In: Arias IM, Alter HJ, Boyer JL, Cohen DE, Shafritz DA, Thorgeirsson SS, Wolkoff AW, editors. The Liver. Wiley; 2020. pp. 455-71. [DOI: 10.1002/9781119436812.ch37] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
204 Arsik I, Frediani JK, Frezza D, Chen W, Ayer T, Keskinocak P, Jin R, Konomi JV, Barlow SE, Xanthakos SA, Lavine JE, Vos MB. Alanine Aminotransferase as a Monitoring Biomarker in Children with Nonalcoholic Fatty Liver Disease: A Secondary Analysis Using TONIC Trial Data. Children (Basel) 2018;5:E64. [PMID: 29799476 DOI: 10.3390/children5060064] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
205 Nahon P, Soubrane O. Fa(s)t assessment of the liver graft: Is it relevant? Journal of Hepatology 2019;70:346-7. [DOI: 10.1016/j.jhep.2018.12.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
206 Genser L, Lim C, Barbier L, Regimbeau JM, Hobeika C, Goumard C, Laurent A, Fuks D, Chiche L, Vibert E, Scatton O; AFC-LLR-2018 Study Group. Assessment of Factors Associated with Morbidity and Textbook Outcomes of Laparoscopic Liver Resection in Obese Patients: A French Nationwide Study. J Am Coll Surg 2022;235:159-71. [PMID: 35675176 DOI: 10.1097/XCS.0000000000000221] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
207 Ariya M, Koohpayeh F, Ghaemi A, Osati S, Davoodi SH, Razzaz JM, Javedan G, Ehrampoush E, Homayounfar R. Assessment of the association between body composition and risk of non-alcoholic fatty liver. PLoS One 2021;16:e0249223. [PMID: 33793621 DOI: 10.1371/journal.pone.0249223] [Reference Citation Analysis]